What Minerva Biolabs does

Minerva Biolabs GmbH is a Berlin-based contamination detection and control company specializing in PCR-based mycoplasma and bacterial testing for the biopharmaceutical and cell therapy industries. The company sells a catalog of more than 40 products organized around three pillars: detection kits (the Venor®GeM family, Venor® Mycoplasma qPCR and dPCR, the NAT-MAT® integrated platform, and the MiQuant® dPCR line for AAV and CAR-T applications), regulatory reference standards (10CFU®, 100CFU®, and 100GC® Mycoplasma Standards designed for EP 2.6.7, USP <77>, and JP 18 G3 compliance), and decontamination and elimination reagents (PCR Clean™, Mycoplasma Off™, Mynox®, WaterShield™, ZellShield®). The underlying technology is proprietary PCR, qPCR, and dPCR chemistry with claimed sensitivity at the 10 CFU detection threshold for NAT-based mycoplasma testing.

The commercial model is product-led and transactional: products are priced individually at €22–€690 per unit and ordered via telephone, email, or a dedicated US storefront (minervabiolabs.us), supplemented by an actively recruited global distributor network. Target customer segments are pharma and biopharmaceutical companies, ATMP (cell and gene therapy) manufacturers, cell culture laboratories, and molecular biology / PCR laboratories, with regulatory compliance as the central value proposition. Beyond consumables, the firm operates an annual international Proficiency Testing Program (€295 per participation) that enables inter-laboratory comparison for NAT-based mycoplasma detection across multiple commercial kit platforms.

Operationally, Minerva Biolabs is small (1–10 employees), privately held, and bootstrapped — no venture capital, private equity, or parent company ownership is disclosed in available source material. Distribution is hybrid, combining direct telephone and email sales in Europe with distributor-led international reach, and the firm maintains a recurring trade fair presence at events including ISCT Asia, the PDA Pharmaceutical Microbiology Conference, analytica Shanghai, PharmaLab Darmstadt, and CellBio San Diego.

Name

Minerva Biolabs

Legal name

Minerva Biolabs GmbH

Website

https://minerva-biolabs.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Minerva Biolabs GmbH is a Berlin-based life sciences company selling PCR-based mycoplasma and bacterial detection kits, pharmacopoeia-compliant reference standards, and decontamination reagents to biopharmaceutical manufacturers, ATMP producers, and cell culture laboratories worldwide.

Ownership category

akta.pro rank

Product category

Molecular Biology Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility) (HLAGADAE)

akta.pro secondary industries

Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Mycoplasma detection kits
• PCR contamination testing
• Biopharmaceutical quality control
• Cell culture contamination control
• Molecular biology reagents

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Detection Kits and Assays: Sale of PCR-based mycoplasma and bacteria detection kits including Venor®GeM product line variants (Classic, OneStep, qEP, qOneStep, Advance). Revenue generated through direct product sales and distributor channels.
2. Reference Standards and Controls: Sale of 10CFU®, 100CFU®, and 100GC® mycoplasma standards used as external positive controls and for validation of detection methods.
3. Proficiency Testing Program: Annual international proficiency testing program for contamination diagnostics. Costs €295 per participation for sample material production, logistics, and evaluation.
4. Decontamination Reagents: Sale of DNA/RNA decontamination products including PCR Clean™, PCR Clean™ Wipes, Mycoplasma Off™, Mycoplasma Off™ Wipes, and WaterShield™.
5. PCR Enzymes and Reagents: MB Taq Polymerase and other PCR reagents for molecular biology applications.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Minerva Biolabs develops, manufactures, and sells molecular contamination detection and control products for cell culture, biopharmaceutical, and ATMP applications. Its core offerings include PCR, qPCR, and dPCR-based mycoplasma detection kits (Venor®GeM family), inactivated reference standards (10CFU®, 100CFU®, 100GC®) for pharmacopoeia-compliant validation, and DNA/mycoplasma decontamination reagents (PCR Clean™, Mycoplasma Off™, Mynox®), supplemented by an annual international Proficiency Testing Program.

Product overview

Minerva Biolabs is a contamination detection and control company offering a comprehensive portfolio of PCR-based detection kits, reference standards, decontamination reagents, and sample preparation products for biopharmaceutical, cell culture, and ATMP manufacturing. The product range centers on mycoplasma and bacterial contamination control with the Venor®GeM family of detection kits (Classic, OneStep, qEP, qOneStep, Advance), complemented by 10CFU®, 100CFU®, and 100GC® Mycoplasma Standards for regulatory compliance (EP 2.6.7, USP <77>, JP 18 G3), and digital PCR solutions (Venor® Mycoplasma dPCR, MiQuant® product line). The portfolio also includes elimination products (Mycoplasma Off™, Mynox®, Mynox® Gold), decontamination reagents (PCR Clean™, WaterShield™, ZellShield®), and supporting services such as the annual Proficiency Testing Program for international laboratory comparison.

Differentiator

Problem solved

Functional benefit

Brands

• Venor®: Mycoplasma detection kit product line including Venor®GeM, Venor®Mycoplasma qPCR, Venor®Mycoplasma dPCR, and related extraction products.
• 100CFU®
• 10CFU®
• 100GC®
• PCR Clean™
• Mycoplasma Off™

Products and services

• Venor®GeM Classic PCR-based mycoplasma detection kit for routine contamination screening of cell cultures and biologicals. Priced at €166 per 25 reactions.
• Venor®GeM OneStep One-step PCR-based mycoplasma detection kit designed for rapid screening of mycoplasma contamination, priced at €179 per 25 reactions.
• Venor®GeM qEP Quantitative real-time PCR kit for enhanced performance mycoplasma detection, priced at €377 per unit.
• Venor®GeM qOneStep One-step quantitative real-time PCR mycoplasma detection kit for rapid quantitative screening.
• Venor®GeM Advance Advanced PCR-based mycoplasma detection kit offering enhanced performance for regulatory-compliant testing.
• Venor® Mycoplasma qPCR Real-time PCR-based detection kit for quantitative mycoplasma contamination screening in cell cultures and biologicals.
• Venor® Mycoplasma dPCR Digital PCR-based detection kit providing highly sensitive mycoplasma detection for regulatory compliance.
• Venor® Bacteria qPCR qPCR-based detection kit for bacterial contamination screening in cell cultures and biologicals, delivering results in less than 3 hours.
• Venor® Mycoplasma Extraction DNA/RNA extraction kit for mycoplasma sample preparation prior to PCR detection, priced at €123 per unit.
• Venor®GeM Sample Preparation Kit Sample preparation kit for mycoplasma detection workflows supporting Venor®GeM assays.
• 10CFU® Mycoplasma Standards Inactivated, non-infectious mycoplasma standards for external positive controls in PCR-based mycoplasma testing, compliant with EP 2.6.7, USP <77>, and JP 18 G3. Available for multiple species at €322–€429.
• 100CFU® Mycoplasma Standards Non-infectious, inactivated mycoplasma reference standards for NAT-based mycoplasma testing of biopharmaceuticals, cell culture-derived products, and ATMPs. Priced around €690 depending on species.
• 100GC® Mycoplasma Standards Purified nucleic acid standards with defined genome copy numbers for product-specific validation of PCR-based mycoplasma testing methods, compliant with EP 2.6.7 (12.2) and USP <77>. Priced around €390.
• 100CFU® Sensitivity Standards Reference materials for determining the limit of detection and for performance verification of PCR-based mycoplasma assays, complementary to 10CFU® Sensitivity Standards for matrix validation.
• PCR Clean™ DNA decontamination reagent effective against amplicon, plasmid, or genomic DNA and RNA from most laboratory surfaces, priced at €22 per 250 ml spray bottle.
• PCR Clean™ Wipes Pre-moistened wipes for DNA decontamination of laboratory surfaces and equipment.
• Mycoplasma Off™ Mycoplasma elimination reagent for decontamination of cell cultures affected by mycoplasma contamination.
• Mycoplasma Off™ Wipes Pre-moistened wipes for mycoplasma elimination from laboratory surfaces.
• Mynox® Mycoplasma elimination reagent for routine decontamination of contaminated cell cultures.
• Mynox® Gold Enhanced formulation mycoplasma elimination reagent for cell culture decontamination.
• MB Taq Polymerase Taq DNA polymerase enzyme for PCR applications in molecular biology workflows, priced at €50 per 50 units.
• MiQuant® AAV ITR 2/6 – dPCR Digital PCR kit for detection of AAV inverted terminal repeats (ITR) 2/6 supporting gene therapy vector characterization.
• MiQuant® AAV ITR 5 – dPCR Digital PCR kit for detection of AAV inverted terminal repeat (ITR) 5 supporting gene therapy vector characterization.
• MiQuant® CAR-T Cell Lenti – dPCR Digital PCR kit for CAR-T cell and lentiviral vector detection in cell therapy manufacturing.
• MiQuant® Residual DNA HEK-293 – dPCR Digital PCR kit for residual DNA detection in HEK-293 cell substrates used in biomanufacturing.
• Proficiency Testing Program 2026 Annual international proficiency testing program for contamination diagnostics in cell cultures and biologicals. Participants receive sample sets, submit results, and obtain certificates of participation. Priced at €295 per participation, plus shipping. Supports inter-laboratory comparison using PCR kits from Minerva Biolabs, Sartorius Stedim, and QIAGEN.

Quantifiable outcome

• Mycoplasma detection in less than 3 hours using Venor® Bacteria qPCR
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Sartorius StedimcoreTechnology or IntegrationSartorius Stedim is explicitly mentioned as one of the approved PCR kit manufacturers whose products can be used in Minerva Biolabs' proficiency testing program alongside their own Venor®GeM products. The proficiency testing program validates NAT-based detection of mycoplasmas using commercially available kits from Sartorius Stedim, QIAGEN, and Minerva Biolabs.
• QIAGENcoreTechnology or IntegrationQIAGEN is explicitly mentioned as one of the approved PCR kit manufacturers whose products (specifically QIAcuity Mycoplasma Quant) can be used in Minerva Biolabs' proficiency testing program. The program enables inter-laboratory comparison for users of QIAGEN mycoplasma detection kits alongside Minerva Biolabs products.
• Global DistributorscoreChannel Partner/ Reseller/ DistributorMinerva Biolabs maintains a network of global distributors to serve customers worldwide. The company actively recruits new distributors and provides information about becoming a distributor through their website. Distributors benefit from distributing contamination control products in their respective countries.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Emerging players

• Eurofins Scientific: Eurofins BioPharma Product Testing offers mycoplasma testing services (including PCR/NAT) as part of its contract lab portfolio, partially overlapping with Minerva's proficiency testing service and kit customer base.
• Charles River Laboratories: Charles River's Biologics Testing Services include mycoplasma contamination testing under GMP, serving the same biopharma and ATMP QC customers that buy Minerva's PCR kits and standards.

Broad incumbents

• Lonza Group: Lonza provides cell and gene therapy manufacturing services including mycoplasma and sterility testing solutions, serving overlapping biopharma and ATMP customers as a broader bioprocess incumbent.
• Roche Diagnostics: Roche operates a much larger diagnostics portfolio including PCR-based kits and qPCR/dPCR platforms used in pharma QC, serving as a broad incumbent that can bundle contamination control with broader offerings.
• Promega Corporation: Promega supplies molecular biology reagents, PCR enzymes, and nucleic acid extraction kits that overlap with Minerva's MB Taq Polymerase, sample preparation, and decontamination products for the same PCR laboratory users.

Direct peers

• Bio-Rad Laboratories: Bio-Rad offers mycoplasma detection kits and digital PCR platforms (QXDx, ddPCR) that overlap with Minerva's Venor dPCR and MiQuant dPCR product families for biopharma analytics.
• Thermo Fisher Scientific: Thermo Fisher's MycoSEQ Mycoplasma Detection Kit and Pharmacogenomics offering compete head-on with Minerva's Venor product line in biopharmaceutical quality control labs.
• QIAGEN: QIAGEN sells the QIAcuity Mycoplasma Quant digital PCR kit and is named alongside Minerva in the same Proficiency Testing Program, overlapping directly on PCR-based mycoplasma detection consumables.
• Merck KGaA (MilliporeSigma): Merck sells the MycoTOOL Mycoplasma Detection Kit and a broad portfolio of bioprocess contamination control products that directly compete with Minerva's Venor kits and standards.
• Sartorius (Stedim Biotech): Sartorius offers NAT-based mycoplasma detection kits used in cell-based bioprocesses and is explicitly named alongside Minerva in the same Proficiency Testing Program, making it the closest direct peer in contamination control.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/minerva-biolabs
• Instagraminstagram.com/minerva_biolabs
• Xx.com/minervabiolabs

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Minerva Biolabs